TMPO and malignant colon neoplasm: We further found that the inhibitor TUB (1–100 μg/ml) significantly blocked the TP5-promoted proliferation inhibition of HCT116 by OXA, whereas the agonist L-Nico promoted this effect of TP5 (Figure 9A, B), implying that nAchRs might be involved in TP5-mediated inhibition of HCT116 colon cancer stem cells inhibition, thereby interrupting the TP5-promoted proliferation inhibition of HCT116 by oxaliplatin.